Thienopyridine Pretreatment in Non ST Elevation ACS syndrome

Original title: Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis. Reference: Bellemain-Appaix A. et al. BMJ. 2014;Epub ahead of print.

This meta-analysis included 7 studies that included a total 32383 patients admitted with non ST elevation ACS; 17545 (54.5%) underwent PCI. These studies were published between 2001 and 2013: 3 were randomized, 1 was a sub study of a randomized study and 3 were observational studies.

Thienopyridine pretreatment varied in the different studies. For most patients it consisted of a 300 mg clopidogrel loading dose, one used a 600 mg and another was left to operator’s criteria. In the ACCOAST study, patients randomized to pretreatment received 30mg of prasugrel at admission and when PCI was required, the loading dose was completed with 30 additional mg. 

Pretreatment was no associated with a lower risk of all cause or cardiovascular death in the whole cohort or in PCI patients, though a significant increase of bleeding was observed.

When looking at randomized studies alone, efficacy was similar but bleeding was similar. In the complete cohort, pretreatment did reduce the secondary end point, a combination of MACE (OR 0.84; IC 95% 0.72 to 0.98); however, when considering only AMI, the difference was not significant (OR 0.81; IC 95% 0.64 to 1.03). Stroke and urgent revascularization were similar despite pretreatment.

In the PCI cohort, pretreatment only reduced urgent revascularization and this benefit was seen in the subgroup of patients from CURE that underwent PCI.

Conclusion

Thyenopiridine pretreatment in non-ST elevation ACS patients does not reduce mortality and causes excess bleeding.

Editorial Comment

The concept of systematic and immediate pretreatment with a P2Y12 receptor antagonist in non-ST elevation ACS patients needs further consideration, especially in the light of the fact that the sub study of CURE PCI patients was carried out more than 10 years ago and that it was not designed to evaluate pretreatment efficacy. In addition, new, more effective P2Y12 receptor inhibitors have come out in recent years. 

SOLACI

More articles by this author

Radial Patency in Coronary Procedures: Is Heparin Enough or Should We Aim for Distal Transradial Access?

Transradial access is the preferred route in most coronary procedures due to its proven reduction in mortality compared to transfemoral access. However, one of...

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT), the optimal long term monotherapy strategy is...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Radial Patency in Coronary Procedures: Is Heparin Enough or Should We Aim for Distal Transradial Access?

Transradial access is the preferred route in most coronary procedures due to its proven reduction in mortality compared to transfemoral access. However, one of...

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT), the optimal long term monotherapy strategy is...

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...